The responses of Aboriginal Canadians to adjuvanted pandemic (H1N1) 2009 influenza vaccine.
Identifieur interne : 000470 ( Main/Exploration ); précédent : 000469; suivant : 000471The responses of Aboriginal Canadians to adjuvanted pandemic (H1N1) 2009 influenza vaccine.
Auteurs : Ethan Rubinstein [Canada] ; Gerald Predy ; Laura Sauvé ; Greg W. Hammond ; Fred Aoki ; Chris Sikora ; Yan Li ; Barbara Law ; Scott Halperin ; David ScheifeleSource :
- CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne [ 1488-2329 ] ; 2011.
Descripteurs français
- KwdFr :
- MESH :
- Wicri :
- geographic : Canada.
English descriptors
- KwdEn :
- MESH :
- chemical : Influenza Vaccines.
- geographic , epidemiology : Canada.
- epidemiology : Influenza, Human.
- prevention & control : Influenza, Human.
- Adult, Female, Humans, Indians, North American, Influenza A Virus, H1N1 Subtype, Male, Middle Aged, Pandemics, Prospective Studies, Young Adult.
Abstract
BACKGROUND
Because many Aboriginal Canadians had severe cases of pandemic (H1N1) 2009 influenza, they were given priority access to vaccine. However, it was not known if the single recommended dose would adequately protect people at high risk, prompting our study to assess responses to the vaccine among Aboriginal Canadians.
METHODS
We enrolled First Nations and Métis adults aged 20-59 years in our prospective cohort study. Participants were given one 0.5-mL dose of ASO3-adjuvanted pandemic (H1N1) 2009 vaccine (Arepanrix, GlaxoSmithKline Canada). Blood samples were taken at baseline and 21-28 days after vaccination. Paired sera were tested for hemagglutination-inhibiting antibodies at a reference laboratory. To assess vaccine safety, we monitored the injection site symptoms of each participant for seven days. We also monitored patients for general symptoms within 7 days of vaccination and any use of the health care system for 21-28 days after vaccination.
RESULTS
We enrolled 138 participants in the study (95 First Nations, 43 Métis), 137 of whom provided all safety data and 136 of whom provided both blood samples. First Nations and Métis participants had similar characteristics, including high rates of chronic health conditions (74.4%-76.8%). Pre-existing antibody to the virus was detected in 34.3% of the participants, all of whom boosted strongly with vaccination (seroprotection rate [titre ≥ 40] 100%, geometric mean titre 531-667). Participants with no pre-existing antibody also responded well. Fifty-eight of 59 (98.3%) First Nations participants showed seroprotection and a geometric mean titre of 353.6; all 30 Métis participants with no pre-existing antibody showed seroprotection and a geometric mean titre of 376.2. Pain at the injection site and general symptoms frequently occurred but were short-lived and generally not severe, although three participants (2.2%) sought medical attention for general symptoms.
INTERPRETATION
First Nations and Métis adults responded robustly to ASO3-adjuvanted pandemic (H1N1) 2009 vaccine. Virtually all participants showed protective titres, including those with chronic health conditions.
DOI: 10.1503/cmaj.110196
PubMed: 21788422
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The responses of Aboriginal Canadians to adjuvanted pandemic (H1N1) 2009 influenza vaccine.</title><author><name sortKey="Rubinstein, Ethan" sort="Rubinstein, Ethan" uniqKey="Rubinstein E" first="Ethan" last="Rubinstein">Ethan Rubinstein</name><affiliation wicri:level="4"><nlm:affiliation>Health Sciences Center, University of Manitoba, Winnipeg, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Health Sciences Center, University of Manitoba, Winnipeg</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation></author><author><name sortKey="Predy, Gerald" sort="Predy, Gerald" uniqKey="Predy G" first="Gerald" last="Predy">Gerald Predy</name></author><author><name sortKey="Sauve, Laura" sort="Sauve, Laura" uniqKey="Sauve L" first="Laura" last="Sauvé">Laura Sauvé</name></author><author><name sortKey="Hammond, Greg W" sort="Hammond, Greg W" uniqKey="Hammond G" first="Greg W" last="Hammond">Greg W. Hammond</name></author><author><name sortKey="Aoki, Fred" sort="Aoki, Fred" uniqKey="Aoki F" first="Fred" last="Aoki">Fred Aoki</name></author><author><name sortKey="Sikora, Chris" sort="Sikora, Chris" uniqKey="Sikora C" first="Chris" last="Sikora">Chris Sikora</name></author><author><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name></author><author><name sortKey="Law, Barbara" sort="Law, Barbara" uniqKey="Law B" first="Barbara" last="Law">Barbara Law</name></author><author><name sortKey="Halperin, Scott" sort="Halperin, Scott" uniqKey="Halperin S" first="Scott" last="Halperin">Scott Halperin</name></author><author><name sortKey="Scheifele, David" sort="Scheifele, David" uniqKey="Scheifele D" first="David" last="Scheifele">David Scheifele</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21788422</idno><idno type="pmid">21788422</idno><idno type="doi">10.1503/cmaj.110196</idno><idno type="wicri:Area/Main/Corpus">000512</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000512</idno><idno type="wicri:Area/Main/Curation">000512</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000512</idno><idno type="wicri:Area/Main/Exploration">000512</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The responses of Aboriginal Canadians to adjuvanted pandemic (H1N1) 2009 influenza vaccine.</title><author><name sortKey="Rubinstein, Ethan" sort="Rubinstein, Ethan" uniqKey="Rubinstein E" first="Ethan" last="Rubinstein">Ethan Rubinstein</name><affiliation wicri:level="4"><nlm:affiliation>Health Sciences Center, University of Manitoba, Winnipeg, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Health Sciences Center, University of Manitoba, Winnipeg</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation></author><author><name sortKey="Predy, Gerald" sort="Predy, Gerald" uniqKey="Predy G" first="Gerald" last="Predy">Gerald Predy</name></author><author><name sortKey="Sauve, Laura" sort="Sauve, Laura" uniqKey="Sauve L" first="Laura" last="Sauvé">Laura Sauvé</name></author><author><name sortKey="Hammond, Greg W" sort="Hammond, Greg W" uniqKey="Hammond G" first="Greg W" last="Hammond">Greg W. Hammond</name></author><author><name sortKey="Aoki, Fred" sort="Aoki, Fred" uniqKey="Aoki F" first="Fred" last="Aoki">Fred Aoki</name></author><author><name sortKey="Sikora, Chris" sort="Sikora, Chris" uniqKey="Sikora C" first="Chris" last="Sikora">Chris Sikora</name></author><author><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name></author><author><name sortKey="Law, Barbara" sort="Law, Barbara" uniqKey="Law B" first="Barbara" last="Law">Barbara Law</name></author><author><name sortKey="Halperin, Scott" sort="Halperin, Scott" uniqKey="Halperin S" first="Scott" last="Halperin">Scott Halperin</name></author><author><name sortKey="Scheifele, David" sort="Scheifele, David" uniqKey="Scheifele D" first="David" last="Scheifele">David Scheifele</name></author></analytic><series><title level="j">CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne</title><idno type="eISSN">1488-2329</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Canada (epidemiology)</term><term>Female</term><term>Humans</term><term>Indians, North American</term><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza Vaccines</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Male</term><term>Middle Aged</term><term>Pandemics</term><term>Prospective Studies</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Canada (épidémiologie)</term><term>Femelle</term><term>Grippe humaine ()</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Indiens d'Amérique Nord</term><term>Jeune adulte</term><term>Mâle</term><term>Pandémies</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Vaccins antigrippaux</term><term>Études prospectives</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Canada</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Canada</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Female</term><term>Humans</term><term>Indians, North American</term><term>Influenza A Virus, H1N1 Subtype</term><term>Male</term><term>Middle Aged</term><term>Pandemics</term><term>Prospective Studies</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Grippe humaine</term><term>Humains</term><term>Indiens d'Amérique Nord</term><term>Jeune adulte</term><term>Mâle</term><term>Pandémies</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Vaccins antigrippaux</term><term>Études prospectives</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Because many Aboriginal Canadians had severe cases of pandemic (H1N1) 2009 influenza, they were given priority access to vaccine. However, it was not known if the single recommended dose would adequately protect people at high risk, prompting our study to assess responses to the vaccine among Aboriginal Canadians.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>We enrolled First Nations and Métis adults aged 20-59 years in our prospective cohort study. Participants were given one 0.5-mL dose of ASO3-adjuvanted pandemic (H1N1) 2009 vaccine (Arepanrix, GlaxoSmithKline Canada). Blood samples were taken at baseline and 21-28 days after vaccination. Paired sera were tested for hemagglutination-inhibiting antibodies at a reference laboratory. To assess vaccine safety, we monitored the injection site symptoms of each participant for seven days. We also monitored patients for general symptoms within 7 days of vaccination and any use of the health care system for 21-28 days after vaccination.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>We enrolled 138 participants in the study (95 First Nations, 43 Métis), 137 of whom provided all safety data and 136 of whom provided both blood samples. First Nations and Métis participants had similar characteristics, including high rates of chronic health conditions (74.4%-76.8%). Pre-existing antibody to the virus was detected in 34.3% of the participants, all of whom boosted strongly with vaccination (seroprotection rate [titre ≥ 40] 100%, geometric mean titre 531-667). Participants with no pre-existing antibody also responded well. Fifty-eight of 59 (98.3%) First Nations participants showed seroprotection and a geometric mean titre of 353.6; all 30 Métis participants with no pre-existing antibody showed seroprotection and a geometric mean titre of 376.2. Pain at the injection site and general symptoms frequently occurred but were short-lived and generally not severe, although three participants (2.2%) sought medical attention for general symptoms.</p></div><div type="abstract" xml:lang="en"><p><b>INTERPRETATION</b></p><p>First Nations and Métis adults responded robustly to ASO3-adjuvanted pandemic (H1N1) 2009 vaccine. Virtually all participants showed protective titres, including those with chronic health conditions.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21788422</PMID><DateCompleted><Year>2011</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1488-2329</ISSN><JournalIssue CitedMedium="Internet"><Volume>183</Volume><Issue>13</Issue><PubDate><Year>2011</Year><Month>Sep</Month><Day>20</Day></PubDate></JournalIssue><Title>CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne</Title><ISOAbbreviation>CMAJ</ISOAbbreviation></Journal><ArticleTitle>The responses of Aboriginal Canadians to adjuvanted pandemic (H1N1) 2009 influenza vaccine.</ArticleTitle><Pagination><MedlinePgn>E1033-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1503/cmaj.110196</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Because many Aboriginal Canadians had severe cases of pandemic (H1N1) 2009 influenza, they were given priority access to vaccine. However, it was not known if the single recommended dose would adequately protect people at high risk, prompting our study to assess responses to the vaccine among Aboriginal Canadians.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We enrolled First Nations and Métis adults aged 20-59 years in our prospective cohort study. Participants were given one 0.5-mL dose of ASO3-adjuvanted pandemic (H1N1) 2009 vaccine (Arepanrix, GlaxoSmithKline Canada). Blood samples were taken at baseline and 21-28 days after vaccination. Paired sera were tested for hemagglutination-inhibiting antibodies at a reference laboratory. To assess vaccine safety, we monitored the injection site symptoms of each participant for seven days. We also monitored patients for general symptoms within 7 days of vaccination and any use of the health care system for 21-28 days after vaccination.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We enrolled 138 participants in the study (95 First Nations, 43 Métis), 137 of whom provided all safety data and 136 of whom provided both blood samples. First Nations and Métis participants had similar characteristics, including high rates of chronic health conditions (74.4%-76.8%). Pre-existing antibody to the virus was detected in 34.3% of the participants, all of whom boosted strongly with vaccination (seroprotection rate [titre ≥ 40] 100%, geometric mean titre 531-667). Participants with no pre-existing antibody also responded well. Fifty-eight of 59 (98.3%) First Nations participants showed seroprotection and a geometric mean titre of 353.6; all 30 Métis participants with no pre-existing antibody showed seroprotection and a geometric mean titre of 376.2. Pain at the injection site and general symptoms frequently occurred but were short-lived and generally not severe, although three participants (2.2%) sought medical attention for general symptoms.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">First Nations and Métis adults responded robustly to ASO3-adjuvanted pandemic (H1N1) 2009 vaccine. Virtually all participants showed protective titres, including those with chronic health conditions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rubinstein</LastName><ForeName>Ethan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Health Sciences Center, University of Manitoba, Winnipeg, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Predy</LastName><ForeName>Gerald</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Sauvé</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Hammond</LastName><ForeName>Greg W</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Aoki</LastName><ForeName>Fred</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Sikora</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Law</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Halperin</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Scheifele</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01001026</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>CMAJ</MedlineTA><NlmUniqueID>9711805</NlmUniqueID><ISSNLinking>0820-3946</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007198" MajorTopicYN="Y">Indians, North American</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="Y">Influenza A Virus, H1N1 Subtype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21788422</ArticleId><ArticleId IdType="pii">cmaj.110196</ArticleId><ArticleId IdType="doi">10.1503/cmaj.110196</ArticleId><ArticleId IdType="pmc">PMC3176866</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Can J Gastroenterol. 2003 Dec;17(12):707-12</Citation><ArticleIdList><ArticleId IdType="pubmed">14679425</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hyg (Lond). 1972 Dec;70(4):767-77</Citation><ArticleIdList><ArticleId IdType="pubmed">4509641</ArticleId></ArticleIdList></Reference><Reference><Citation>Can Commun Dis Rep. 2008 Jul;34(ACS-3):1-46</Citation><ArticleIdList><ArticleId IdType="pubmed">18802991</ArticleId></ArticleIdList></Reference><Reference><Citation>J Viral Hepat. 2009 Apr;16(4):292-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19175873</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2009 Jun 25;459(7250):1122-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19516283</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2011 Mar 21;29(14):2576-81</Citation><ArticleIdList><ArticleId IdType="pubmed">21296693</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2009 Dec 11;58(48):1341-4</Citation><ArticleIdList><ArticleId IdType="pubmed">20010508</ArticleId></ArticleIdList></Reference><Reference><Citation>CMAJ. 2010 Feb 23;182(3):257-64</Citation><ArticleIdList><ArticleId IdType="pubmed">20093297</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2010 Jun 1;201(11):1644-53</Citation><ArticleIdList><ArticleId IdType="pubmed">20423222</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2010 Sep 15;51(6):668-77</Citation><ArticleIdList><ArticleId IdType="pubmed">20687838</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2009 Nov 4;302(17):1872-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19822627</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country><region><li>Manitoba</li></region><settlement><li>Winnipeg</li></settlement><orgName><li>Université du Manitoba</li></orgName></list><tree><noCountry><name sortKey="Aoki, Fred" sort="Aoki, Fred" uniqKey="Aoki F" first="Fred" last="Aoki">Fred Aoki</name><name sortKey="Halperin, Scott" sort="Halperin, Scott" uniqKey="Halperin S" first="Scott" last="Halperin">Scott Halperin</name><name sortKey="Hammond, Greg W" sort="Hammond, Greg W" uniqKey="Hammond G" first="Greg W" last="Hammond">Greg W. Hammond</name><name sortKey="Law, Barbara" sort="Law, Barbara" uniqKey="Law B" first="Barbara" last="Law">Barbara Law</name><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name><name sortKey="Predy, Gerald" sort="Predy, Gerald" uniqKey="Predy G" first="Gerald" last="Predy">Gerald Predy</name><name sortKey="Sauve, Laura" sort="Sauve, Laura" uniqKey="Sauve L" first="Laura" last="Sauvé">Laura Sauvé</name><name sortKey="Scheifele, David" sort="Scheifele, David" uniqKey="Scheifele D" first="David" last="Scheifele">David Scheifele</name><name sortKey="Sikora, Chris" sort="Sikora, Chris" uniqKey="Sikora C" first="Chris" last="Sikora">Chris Sikora</name></noCountry><country name="Canada"><region name="Manitoba"><name sortKey="Rubinstein, Ethan" sort="Rubinstein, Ethan" uniqKey="Rubinstein E" first="Ethan" last="Rubinstein">Ethan Rubinstein</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000470 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000470 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeCanadaV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:21788422
|texte= The responses of Aboriginal Canadians to adjuvanted pandemic (H1N1) 2009 influenza vaccine.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21788422" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV3
| This area was generated with Dilib version V0.6.35. |  |